Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

220 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TrkB is responsible for EMT transition in malignant pleural effusions derived cultures from adenocarcinoma of the lung.
Ricci A, De Vitis C, Noto A, Fattore L, Mariotta S, Cherubini E, Roscilli G, Liguori G, Scognamiglio G, Rocco G, Botti G, Giarnieri E, Giovagnoli MR, De Toma G, Ciliberto G, Mancini R. Ricci A, et al. Among authors: fattore l. Cell Cycle. 2013 Jun 1;12(11):1696-703. doi: 10.4161/cc.24759. Epub 2013 May 2. Cell Cycle. 2013. PMID: 23656788 Free PMC article.
Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma.
Fattore L, Malpicci D, Marra E, Belleudi F, Noto A, De Vitis C, Pisanu ME, Coluccia P, Camerlingo R, Roscilli G, Ribas A, Di Napoli A, Torrisi MR, Aurisicchio L, Ascierto PA, Mancini R, Ciliberto G. Fattore L, et al. Oncotarget. 2015 Sep 22;6(28):24823-41. doi: 10.18632/oncotarget.4485. Oncotarget. 2015. PMID: 26208478 Free PMC article.
miR-579-3p controls melanoma progression and resistance to target therapy.
Fattore L, Mancini R, Acunzo M, Romano G, Laganà A, Pisanu ME, Malpicci D, Madonna G, Mallardo D, Capone M, Fulciniti F, Mazzucchelli L, Botti G, Croce CM, Ascierto PA, Ciliberto G. Fattore L, et al. Proc Natl Acad Sci U S A. 2016 Aug 23;113(34):E5005-13. doi: 10.1073/pnas.1607753113. Epub 2016 Aug 8. Proc Natl Acad Sci U S A. 2016. PMID: 27503895 Free PMC article.
MicroRNAs in melanoma development and resistance to target therapy.
Fattore L, Costantini S, Malpicci D, Ruggiero CF, Ascierto PA, Croce CM, Mancini R, Ciliberto G. Fattore L, et al. Oncotarget. 2017 Mar 28;8(13):22262-22278. doi: 10.18632/oncotarget.14763. Oncotarget. 2017. PMID: 28118616 Free PMC article. Review.
Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma.
Fattore L, Ruggiero CF, Pisanu ME, Liguoro D, Cerri A, Costantini S, Capone F, Acunzo M, Romano G, Nigita G, Mallardo D, Ragone C, Carriero MV, Budillon A, Botti G, Ascierto PA, Mancini R, Ciliberto G. Fattore L, et al. Cell Death Differ. 2019 Jul;26(7):1267-1282. doi: 10.1038/s41418-018-0205-5. Epub 2018 Sep 25. Cell Death Differ. 2019. PMID: 30254376 Free PMC article.
220 results